{"id":"https://openalex.org/W4392853828","doi":"https://doi.org/10.1136/lupus-2024-el.217","title":"P163 Efficacy of deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, in musculoskeletal manifestations of systemic lupus erythematosus: a subanalysis of the phase 2 PAISLEY study","display_name":"P163 Efficacy of deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, in musculoskeletal manifestations of systemic lupus erythematosus: a subanalysis of the phase 2 PAISLEY study","publication_year":2024,"publication_date":"2024-03-01","ids":{"openalex":"https://openalex.org/W4392853828","doi":"https://doi.org/10.1136/lupus-2024-el.217"},"language":"en","primary_location":{"id":"doi:10.1136/lupus-2024-el.217","doi":"https://doi.org/10.1136/lupus-2024-el.217","is_oa":true,"landing_page_url":"https://doi.org/10.1136/lupus-2024-el.217","pdf_url":"https://lupus.bmj.com/content/lupusscimed/11/Suppl_1/A165.2.full.pdf","source":{"id":"https://openalex.org/S2764956401","display_name":"Lupus Science & Medicine","issn_l":"2053-8790","issn":["2053-8790"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Poster Presentations","raw_type":"proceedings-article"},"volume":null,"type":"conference-paper","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://lupus.bmj.com/content/lupusscimed/11/Suppl_1/A165.2.full.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5108536115","display_name":"Marilyn C. Pike","orcid":"https://orcid.org/0009-0007-7760-5293","observed_orcids":["https://orcid.org/0009-0007-7760-5293"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Marilyn Pike","raw_affiliation_strings":["Rheumatology, MedPharm Consulting, Inc, Raleigh, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rheumatology, MedPharm Consulting, Inc, Raleigh, NC, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003469260","display_name":"Amit Saxena","orcid":"https://orcid.org/0000-0003-0098-1083","observed_orcids":["https://orcid.org/0000-0003-0098-1083"]},"institutions":[{"id":"https://openalex.org/I57206974","display_name":"New York University","ror":"https://ror.org/0190ak572","country_code":"US","type":"education","lineage":["https://openalex.org/I57206974"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amit Saxena","raw_affiliation_strings":["Dept. of Medicine, Division of Rheumatology, NYU Grossman School of Medicine, New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dept. of Medicine, Division of Rheumatology, NYU Grossman School of Medicine, New York, NY, USA","institution_ids":["https://openalex.org/I57206974"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076651506","display_name":"Richard Alan Furie","orcid":"https://orcid.org/0000-0001-6712-1585","observed_orcids":["https://orcid.org/0000-0001-6712-1585"]},"institutions":[{"id":"https://openalex.org/I1302444339","display_name":"Northwell Health","ror":"https://ror.org/02bxt4m23","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1302444339"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard Furie","raw_affiliation_strings":["Rheumatology, Northwell Health, Great Neck, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rheumatology, Northwell Health, Great Neck, NY, USA","institution_ids":["https://openalex.org/I1302444339"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011826741","display_name":"Peter T. Nash","orcid":"https://orcid.org/0000-0002-2571-788X","observed_orcids":["https://orcid.org/0000-0002-2571-788X"]},"institutions":[{"id":"https://openalex.org/I165143802","display_name":"The University of Queensland","ror":"https://ror.org/00rqy9422","country_code":"AU","type":"education","lineage":["https://openalex.org/I165143802"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Peter Nash","raw_affiliation_strings":["Dept. of Medicine, University of Queensland, Brisbane, QLD, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dept. of Medicine, University of Queensland, Brisbane, QLD, Australia","institution_ids":["https://openalex.org/I165143802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086942556","display_name":"Thomas D\u00f6rner","orcid":"https://orcid.org/0000-0002-6478-7725","observed_orcids":["https://orcid.org/0000-0002-6478-7725"]},"institutions":[{"id":"https://openalex.org/I7877124","display_name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","ror":"https://ror.org/001w7jn25","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I7877124"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Thomas D\u00f6rner","raw_affiliation_strings":["Charit\u00e9 University Hospitals, Berlin, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Charit\u00e9 University Hospitals, Berlin, Germany","institution_ids":["https://openalex.org/I7877124"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062998292","display_name":"Coburn Hobar","orcid":"https://orcid.org/0009-0006-5935-7997","observed_orcids":["https://orcid.org/0009-0006-5935-7997"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Coburn Hobar","raw_affiliation_strings":["Bristol Myers Squibb, Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108909033","display_name":"Samantha Pomponi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Samantha Pomponi","raw_affiliation_strings":["Bristol Myers Squibb, Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5094164897","display_name":"Ravi Koti","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210105783","display_name":"Syneos Health (United States)","ror":"https://ror.org/01r74wp43","country_code":"US","type":"company","lineage":["https://openalex.org/I4210105783"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ravi Koti","raw_affiliation_strings":["Syneos Health, Morrisville, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Syneos Health, Morrisville, NC, USA","institution_ids":["https://openalex.org/I4210105783"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004760940","display_name":"Subhashis Banerjee","orcid":"https://orcid.org/0009-0000-1365-5207","observed_orcids":["https://orcid.org/0009-0000-1365-5207","https://orcid.org/0000-0001-8971-0006"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Subhashis Banerjee","raw_affiliation_strings":["Bristol Myers Squibb, Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018812946","display_name":"Thomas Wegman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas Wegman","raw_affiliation_strings":["Bristol Myers Squibb, Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5052053321","display_name":"Joan T. Merrill","orcid":"https://orcid.org/0000-0002-4514-2382","observed_orcids":["https://orcid.org/0000-0002-4514-2382"]},"institutions":[{"id":"https://openalex.org/I30558944","display_name":"Oklahoma Medical Research Foundation","ror":"https://ror.org/035z6xf33","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I30558944"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joan Merrill","raw_affiliation_strings":["Oklahoma Medical Research Foundation Oklahoma City, OK, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oklahoma Medical Research Foundation Oklahoma City, OK, USA","institution_ids":["https://openalex.org/I30558944"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":7,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":1950,"currency":"GBP","value_usd":2391},"apc_paid":{"value":1950,"currency":"GBP","value_usd":2391},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.07692308,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"A165.2","last_page":"A167"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10308","display_name":"Systemic Lupus Erythematosus Research","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10308","display_name":"Systemic Lupus Erythematosus Research","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11330","display_name":"Systemic Sclerosis and Related Diseases","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/deucravacitinib","display_name":"deucravacitinib","score":0.9610000252723694},{"id":"https://openalex.org/keywords/systemic-lupus-erythematosus","display_name":"systemic lupus erythematosus","score":0.9980000257492065},{"id":"https://openalex.org/keywords/musculoskeletal-manifestations","display_name":"musculoskeletal manifestations","score":0.9900000095367432},{"id":"https://openalex.org/keywords/joint-count","display_name":"joint count","score":0.3630000054836273},{"id":"https://openalex.org/keywords/swollen-joint-count","display_name":"swollen joint count","score":0.8190000057220459},{"id":"https://openalex.org/keywords/tender-joint-count","display_name":"tender joint count","score":0.9860000014305115},{"id":"https://openalex.org/keywords/oral-tyrosine-kinase-inhibitor","display_name":"oral tyrosine kinase inhibitor","score":0.7239999771118164},{"id":"https://openalex.org/keywords/sle-responder-index-4","display_name":"SLE Responder Index 4","score":0.824999988079071},{"id":"https://openalex.org/keywords/disease-activity","display_name":"disease activity","score":0.6240000128746033},{"id":"https://openalex.org/keywords/drug-efficacy","display_name":"drug efficacy","score":0.3619999885559082},{"id":"https://openalex.org/keywords/dose-comparison","display_name":"dose comparison","score":0.6190000176429749},{"id":"https://openalex.org/keywords/non-responder-imputation","display_name":"non-responder imputation","score":0.703000009059906},{"id":"https://openalex.org/keywords/rheumatoid-factor","display_name":"rheumatoid factor","score":0.3930000066757202},{"id":"https://openalex.org/keywords/anti-ccp-antibodies","display_name":"anti-CCP antibodies","score":0.4869999885559082}],"concepts":[{"id":"https://openalex.org/C166342909","wikidata":"https://www.wikidata.org/wiki/Q845326","display_name":"Allosteric regulation","level":3,"score":0.5825406312942505},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.5715398192405701},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.521261990070343},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.49744322896003723},{"id":"https://openalex.org/C2776912625","wikidata":"https://www.wikidata.org/wiki/Q1485","display_name":"Systemic lupus erythematosus","level":3,"score":0.4603841304779053},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.40390777587890625},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.35908031463623047},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.26029011607170105},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.11504408717155457},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.0670030415058136},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.055350810289382935}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1136/lupus-2024-el.217","doi":"https://doi.org/10.1136/lupus-2024-el.217","is_oa":true,"landing_page_url":"https://doi.org/10.1136/lupus-2024-el.217","pdf_url":"https://lupus.bmj.com/content/lupusscimed/11/Suppl_1/A165.2.full.pdf","source":{"id":"https://openalex.org/S2764956401","display_name":"Lupus Science & Medicine","issn_l":"2053-8790","issn":["2053-8790"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Poster Presentations","raw_type":"proceedings-article"},{"id":"pmh:oai:doaj.org/article:faf247927fb4430283d6619bc5ef7574","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/faf247927fb4430283d6619bc5ef7574","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Lupus Science and Medicine, Vol 11, Iss Suppl 1 (2024)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1136/lupus-2024-el.217","doi":"https://doi.org/10.1136/lupus-2024-el.217","is_oa":true,"landing_page_url":"https://doi.org/10.1136/lupus-2024-el.217","pdf_url":"https://lupus.bmj.com/content/lupusscimed/11/Suppl_1/A165.2.full.pdf","source":{"id":"https://openalex.org/S2764956401","display_name":"Lupus Science & Medicine","issn_l":"2053-8790","issn":["2053-8790"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Poster Presentations","raw_type":"proceedings-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"},{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"},{"id":"https://openalex.org/F4320307781","display_name":"Sanofi","ror":"https://ror.org/027vj4x92"},{"id":"https://openalex.org/F4320309086","display_name":"Celgene","ror":"https://ror.org/0527yg379"},{"id":"https://openalex.org/F4320320879","display_name":"Deutsche Forschungsgemeinschaft","ror":"https://ror.org/018mejw64"},{"id":"https://openalex.org/F4320332193","display_name":"Genentech","ror":"https://ror.org/04gndp242"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4392853828.pdf","grobid_xml":"https://content.openalex.org/works/W4392853828.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4399481366","https://openalex.org/W4392853689","https://openalex.org/W4399481233","https://openalex.org/W4399481376","https://openalex.org/W4297317388","https://openalex.org/W4399481644","https://openalex.org/W4324057491","https://openalex.org/W4290997437","https://openalex.org/W4411411027","https://openalex.org/W4308834504"],"abstract_inverted_index":{"Objective":[0],"Deucravacitinib,":[1],"a":[2,50,174,333,393],"first-in-class,":[3],"oral,":[4],"selective,":[5],"allosteric":[6],"tyrosine":[7],"kinase":[8],"2":[9,41],"inhibitor":[10],"targets":[11],"select":[12],"immune":[13],"pathways":[14],"relevant":[15],"to":[16,56,98,284,506],"systemic":[17],"lupus":[18],"erythematosus":[19],"(SLE)":[20],"and":[21,70,132,142,149,295,302,314,342,355,399,414,425,428,435,443,456,474,486,491,494,537],"is":[22],"approved":[23],"in":[24,87,136,154,287,309,327],"multiple":[25],"countries":[26],"for":[27,44,182,345],"the":[28,37,62,66,88,187,353,366],"treatment":[29],"of":[30,53,65,128,299,312,335,390],"adults":[31],"with":[32,46,156,164,173,206,244,305,325],"moderate-to-severe":[33],"plaque":[34],"psoriasis.":[35],"In":[36],"48-week,":[38],"double-blind,":[39],"phase":[40],"PAISLEY":[42,89],"trial":[43],"patients":[45,54,155,163,205,354],"active":[47,137,208],"SLE":[48,67],"(NCT03252587),":[49],"greater":[51],"proportion":[52],"randomized":[55,96],"deucravacitinib":[57,102,213,220,251,262,306],"3":[58,103,221,263],"mg":[59,104,108,113,222,226,230,264,268,272],"BID":[60,105,109],"met":[61],"primary":[63],"endpoint":[64,200],"Responder":[68],"Index-4":[69],"all":[71],"key":[72],"secondary":[73],"endpoints,":[74],"including":[75],"global":[76],"disease":[77],"activity":[78],"measures.":[79],"This":[80,371],"post-hoc":[81],"subanalysis":[82],"focuses":[83],"on":[84],"musculoskeletal":[85,346],"manifestations":[86],"study.":[90],"Methods":[91],"Patients":[92,243],"receiving":[93,212,250],"standard-of-care":[94],"were":[95,171,193,282,307],"1:1:1:1":[97],"placebo":[99,217,257,331],"(n=90)":[100],"or":[101,111,123,162],"(n=91),":[106],"6":[107,225,267],"(n=93),":[110],"12":[112,229,271],"QD":[114],"(n=89).":[115],"A":[116],"40-joint":[117],"count":[118,139,147,152],"measured":[119],"joint":[120,138,146,151,166,246,328,340],"swelling,":[121],"tenderness,":[122],"both.":[124],"Outcomes":[125],"included":[126],"achievement":[127],"\u226550%":[129],"reduction":[130,134],"(JC-50)":[131],"100%":[133],"(JC-100)":[135],"(swollen+tender;":[140],"AJC-50":[141,215,253,285],"AJC-100,":[143],"respectively),":[144],"swollen":[145],"(SJC),":[148],"tender":[150],"(TJC)":[153],"\u22656":[157,207],"joints":[158,209],"involved":[159],"at":[160,168,210,240,248,348],"baseline":[161,211,249],"any":[165,245],"involvement":[167,247,347],"baseline.":[169,349],"Responses":[170],"reported":[172,237],"prespecified":[175],"nonresponder":[176],"imputation.":[177],"The":[178],"2-sided":[179],"95%":[180],"CI":[181],"responses":[183,304],"was":[184,323,373,383],"calculated":[185],"using":[186,332],"asymptotic":[188],"(including":[189],"continuity)":[190],"method.":[191],"Results":[192,195],"descriptive.":[194],"At":[196],"week":[197,241,276,291,317],"32":[198],"(primary":[199],"analysis":[201],"time":[202,337],"point),":[203],"more":[204,254],"achieved":[214,252],"vs":[216,256,330],"(placebo,":[218],"45.3%;":[219],"BID,":[223,227,265,269],"63.5%;":[224],"64.6%;":[228],"QD,":[231,273],"56.5%;":[232],"figure":[233],"1A),":[234],"expanding":[235],"previously":[236],"JC-50":[238,301],"findings":[239],"48.":[242],"often":[255],"(week":[258],"32:":[259],"placebo,":[260],"48.3%;":[261],"63.3%;":[266],"63.4%;":[270],"53.4%)":[274],"through":[275,290,316],"48":[277,292,318],"(figure":[278,293,319],"1B).":[279],"AJC-100":[280],"results":[281,286],"similar":[283],"both":[288],"populations":[289],"1C":[294],"1D).":[296],"Consistent":[297],"patterns":[298],"higher":[300],"JC-100":[303],"observed":[308],"separate":[310],"analyses":[311],"SJC":[313],"TJC":[315],"2).":[320],"Conclusion":[321],"Deucravacitinib":[322],"associated":[324],"reductions":[326],"counts":[329],"range":[334],"assessment":[336],"points,":[338],"different":[339,343],"assessments,":[341],"cutoffs":[344],"Acknowledgements":[350],"We":[351],"thank":[352],"their":[356],"families":[357],"who":[358,369],"made":[359],"this":[360],"study":[361,372],"possible,":[362],"as":[363,365],"well":[364],"clinical":[367],"teams":[368],"participated.":[370],"sponsored":[374],"by":[375,385,401],"Bristol":[376,402,410,420,437,447,463,496,507,518],"Myers":[377,403,411,421,438,448,464,497,508,519],"Squibb.":[378,404],"Professional":[379],"medical":[380],"writing":[381],"assistance":[382],"provided":[384],"Stephanie":[386],"V.":[387],"Koebele,":[388],"PhD,":[389],"SciMentum,":[391],"Inc,":[392,397],"Nucleus":[394],"Group":[395],"Holdings,":[396],"company,":[398],"funded":[400],"COI":[405],"Disclosures":[406],"MP:":[407],"Consultancy:":[408,511],"AstraZeneca,":[409,419,515],"Squibb,":[412,422,449,465,520],"Pfizer,":[413],"UCB":[415,457,487],"AS:":[416],"Advisory":[417,477],"board:":[418],"Eli":[423,452,469,482,529],"Lilly":[424],"Company,":[426],"GSK,":[427,526],"Kezar":[429],"Life":[430],"Sciences":[431],"RF:":[432],"Research/grant":[433,441,459],"support":[434,442],"consultancy:":[436,444],"Squibb":[439,498,509],"PN:":[440],"AbbVie,":[445,461,479,512],"Amgen,":[446,514],"Celgene,":[450],"Janssen,":[451,466,528],"Lilly,":[453,470,483,530],"Novartis,":[454,462,484],"Servatus,":[455],"TD:":[458],"support:":[460],"Roche/Genentech,":[467],"Sanofi,":[468,485,535],"UCB,":[471],"Deutsche":[472],"Forschungsgemeinschaft,":[473],"EU":[475],"Horizon/HarmonicSS.":[476],"boards/panels:":[478],"Aurinia,":[480,516],"Bristol-Myers-Squibb,":[481],"CH,":[488],"SP,":[489],"SB,":[490],"TW:":[492],"Employee":[493],"shareholder:":[495],"RK:":[499],"Employee:":[500],"Syneos":[501],"Health,":[502],"providing":[503],"statistical":[504],"services":[505],"JM:":[510],"Alexion,":[513],"Biogen,":[517],"EMD":[521],"Serono,":[522],"Equillium,":[523],"Genentech,":[524],"Gilead,":[525],"IQVIA,":[527],"LFA,":[531],"Merck,":[532],"Provention,":[533],"Remegen,":[534],"Takeda,":[536],"Zenas":[538]},"counts_by_year":[],"updated_date":"2026-11-02T09:45:03.842371","created_date":"2024-03-16T00:00:00"}